Literature DB >> 24247821

Vascular endothelial growth factor and the kidney: something of the marvellous.

Andrew Advani1.   

Abstract

PURPOSE OF REVIEW: The vascular endothelial growth factor (VEGF) system is a multifarious network and an exemplar of an intraglomerular signalling pathway. Here, we review recent advances that highlight the subtle nature of the renal VEGF system and its influencers. RECENT
FINDINGS: The VEGF system is no longer considered as a simple paracrine, ligand-receptor interaction under the regulatory control of a soluble 'decoy', soluble fms-like tyrosine kinase-1 (sFLT1). Rather, the abundantly expressed, podocyte-derived VEGF isoform, VEGF-A, is now recognized to mediate both paracrine effects across the filtration barrier and autocrine actions, functioning to preserve the integrity of the cells from which it arises. Autocrine actions of the podocyte VEGF system extend beyond those of the VEGF-A isoform, however, with sFLT1 itself now appreciated as regulating podocyte morphology by binding to lipid microdomains. These and other functions of the VEGF system are profoundly affected by the presence, nature and abundance of influencers both intrinsic and extrinsic to the pathway, the latter most readily exemplified by the role of the cytokine in the diabetic kidney.
SUMMARY: The glomerular VEGF system plays a delicate, yet critical, role in preserving renal homeostasis. It may be intricate, but 'in all things of nature there is something of the marvellous'.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24247821     DOI: 10.1097/01.mnh.0000437329.41546.a9

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  9 in total

Review 1.  Signal transduction in podocytes--spotlight on receptor tyrosine kinases.

Authors:  Jochen Reiser; Sanja Sever; Christian Faul
Journal:  Nat Rev Nephrol       Date:  2014-01-07       Impact factor: 28.314

2.  Blocking VEGF/Caveolin-1 signaling contributes to renal protection of fasudil in streptozotocin-induced diabetic rats.

Authors:  Jing Jin; Chao Peng; Su-zhen Wu; Hong-min Chen; Bai-fang Zhang
Journal:  Acta Pharmacol Sin       Date:  2015-05-04       Impact factor: 6.150

Review 3.  Clinical therapeutic strategies for early stage of diabetic kidney disease.

Authors:  Munehiro Kitada; Keizo Kanasaki; Daisuke Koya
Journal:  World J Diabetes       Date:  2014-06-15

Review 4.  Therapeutic angiogenesis by vascular endothelial growth factor supplementation for treatment of renal disease.

Authors:  Omar C Logue; Jeremy W D McGowan; Eric M George; Gene L Bidwell
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-09       Impact factor: 2.894

5.  Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report.

Authors:  Shoko Ochiai; Yuji Sato; Akihiro Minakawa; Akihiro Fukuda; Shouichi Fujimoto
Journal:  BMC Nephrol       Date:  2019-03-07       Impact factor: 2.388

Review 6.  Nephrotic syndrome associated with ramucirumab therapy: A single-center case series and literature review.

Authors:  Teruhiro Fujii; Kentaro Kawasoe; Akiko Tonooka; Akihito Ohta; Kosaku Nitta
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

Review 7.  Role of Podocyte Injury in Glomerulosclerosis.

Authors:  Chen-Chen Lu; Gui-Hua Wang; Jian Lu; Pei-Pei Chen; Yang Zhang; Ze-Bo Hu; Kun-Ling Ma
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 8.  Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations.

Authors:  Luca Piscitani; Vittorio Sirolli; Lorenzo Di Liberato; Manrico Morroni; Mario Bonomini
Journal:  Int J Mol Sci       Date:  2020-07-10       Impact factor: 5.923

9.  The PKGIα/VASP pathway is involved in insulin- and high glucose-dependent regulation of albumin permeability in cultured rat podocytes.

Authors:  Patrycja Rachubik; Maria Szrejder; Irena Audzeyenka; Dorota Rogacka; Michał Rychłowski; Stefan Angielski; Agnieszka Piwkowska
Journal:  J Biochem       Date:  2020-12-26       Impact factor: 3.387

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.